middl
east
respiratori
syndrom
mer
caus
novel
betacoronaviru
merscov
isol
late
saudi
arabia
syndrom
mer
describ
viral
infect
caus
fever
cough
andor
short
breath
lesser
extent
gastrointestin
symptom
diarrhea
sever
diseas
merscov
infect
caus
respiratori
failur
organ
failur
case
fatal
especi
patient
comorbid
diabet
cardiac
complic
howev
infect
asymptomat
mild
mani
case
merscov
spread
countri
infect
human
mortal
rate
dromedari
camel
especi
juvenil
contract
infect
shed
viru
without
notabl
symptom
diseas
known
occur
sinc
earli
mechan
camel
human
transmiss
still
clear
sever
primari
case
associ
camel
contact
consid
import
risk
factor
therefor
camel
consid
intermedi
host
one
sourc
merscov
infect
livestock
anim
sheep
goat
cow
chicken
hors
prove
seroneg
mani
studi
anim
product
contract
merscov
inocul
experiment
therefor
date
dromedari
camel
confirm
anim
reservoir
current
approv
vaccin
camel
human
despit
activ
vaccin
research
develop
number
vaccin
candid
develop
use
variou
platform
regimen
test
sever
anim
model
viral
vector
potent
platform
technolog
utilis
develop
vaccin
malaria
tuberculosi
influenza
hiv
hcv
ebola
mani
viral
pathogen
vector
includ
adenovirus
poxvirus
yellow
fever
virus
alphavirus
prefer
abil
induc
cellular
immun
respons
addit
humor
immun
report
develop
merscov
vaccin
candid
base
two
differ
viral
vector
chimpanze
adenoviru
oxford
univers
modifi
vaccinia
viru
ankara
mva
viral
vector
develop
gener
two
altern
version
result
four
vaccin
candid
encod
complet
merscov
spike
gene
two
base
vaccin
produc
without
signal
peptid
human
tissu
plasminogen
activ
gene
tpa
n
terminu
previou
studi
shown
encod
tpa
upstream
recombin
antigen
enhanc
immunogenc
although
result
differ
depend
antigen
employ
tpa
encod
upstream
influenza
viru
nucleoprotein
dna
vector
enhanc
cellular
humor
immun
respons
mice
wherea
leader
sequenc
result
increas
humor
sequenc
decreas
cellular
respons
hiv
gag
two
mva
base
vaccin
produc
either
poxvir
promot
drive
antigen
express
includ
tpa
sequenc
n
terminu
merscov
spike
protein
previous
report
abil
strong
earli
promot
enhanc
cellular
immunogen
vaccin
antigen
candid
malaria
influenza
compar
utilis
earlyl
promot
result
lower
level
gene
express
immedi
viru
infect
target
cell
higher
level
later
stage
continu
assess
promot
enhanc
cellular
immunogen
investig
abil
impact
humor
immun
respons
four
vaccin
candid
evalu
number
differ
regimen
mous
model
show
singl
dose
mer
induc
higher
cellular
humor
immunogen
singl
dose
mva
mer
equival
two
dose
mva
mer
base
vaccin
test
differ
anim
model
includ
camel
human
clinic
trial
prove
safe
immunogen
therefor
base
data
mer
readili
develop
use
mer
vaccin
human
furthermor
utilis
mer
camel
vaccin
serv
onehealth
approach
wherebi
block
merscov
transmiss
camel
expect
prevent
human
infect
spike
gene
merscov
camel
isol
genbank
access
number
synthesis
geneart
gene
synthesi
thermo
fisher
scientif
transgen
clone
four
shuttl
plasmid
vector
follow
infus
clone
clontech
two
plasmid
contain
transgen
within
homolog
region
driven
human
cytomegaloviru
major
immedi
earli
promot
ie
cmv
includ
intron
one
shuttl
plasmid
design
includ
tpa
signal
sequenc
upstream
transgen
sequenc
second
plasmid
contain
tpa
shuttl
plasmid
contain
transgen
within
recombin
cassett
construct
mva
mer
one
shuttl
plasmid
mva
design
upstream
downstream
flank
orf
homolog
sequenc
arm
insert
transgen
within
arm
enabl
utilis
endogen
promot
part
right
homolog
arm
delet
nativ
orf
result
shuttl
vector
gener
mer
shuttl
vector
promot
sequenc
subclon
upstream
transgen
transgen
subclon
shuttl
vector
result
shuttl
vector
gener
mer
shuttl
vector
mer
contain
promot
locu
howev
endogen
promot
intact
locat
upstream
promot
endogen
promot
could
replac
sinc
part
essenti
upstream
orf
shuttl
plasmid
describ
use
valid
express
merscov
spike
protein
vitro
african
green
monkey
kidney
cell
line
vero
cell
seed
plate
confluenc
plasmid
dna
transfect
vero
cell
use
thermo
fisher
scientif
follow
manufactur
instruct
twentyfour
hour
transfect
cell
fix
permeabilis
immunostain
use
rabbit
polyclon
antimerscov
spike
antibodi
follow
standard
protocol
dapi
stain
use
label
nuclei
mer
vaccin
prepar
recombin
destin
dna
bac
vector
describ
entri
plasmid
contain
code
sequenc
merscov
spike
gene
shuttl
vector
explain
accord
standard
protocol
mer
genom
deriv
cell
line
invitrogen
cat
result
virus
purifi
cscl
gradient
ultracentrifug
previous
describ
titr
determin
cell
use
antihexon
immunostain
assay
base
adenoviru
titer
immunoassay
kit
cell
biolab
inc
mva
mer
vaccin
chicken
embryo
fibroblast
cell
cef
infect
mva
parent
viru
encod
dsred
marker
instead
nativ
orf
transfect
mva
shuttl
plasmid
contain
merscov
spike
gene
explain
allow
recombin
mva
genom
delet
dsred
marker
whilst
keep
promot
sequenc
recombin
mva
express
merscov
protein
purifi
plaquepick
fluoresc
select
use
sort
function
cyclon
robot
modul
moflo
flow
cytomet
dako
cytom
denmark
previous
describ
mer
mer
confirm
lack
nativ
orf
dsred
marker
contain
merscov
pcr
ident
puriti
pcr
screen
sequenc
transgen
amplifi
vaccin
confirm
recombin
virus
vaccin
amplifi
monolay
cef
cell
partial
purifi
sucros
cushion
titrat
cef
cell
accord
standard
practic
puriti
ident
verifi
pcr
femal
balbc
mice
harlan
uk
age
week
immunis
intramuscularli
im
upper
leg
total
volum
total
iu
mer
without
tpa
total
pfu
either
mer
mer
induct
shortterm
anaesthesia
anim
anaesthetis
use
vaporis
isofloh
prime
regimen
mice
vaccin
blood
sampl
taken
day
post
immunis
dpi
dpi
serum
isol
spleen
collect
dpi
heterolog
primeboost
regimen
mice
vaccin
mer
boost
mva
mer
dpi
mice
bled
dpi
postprim
dpi
day
postboost
serum
isol
spleen
collect
dpi
homolog
regimen
mice
vaccin
mva
mer
boost
mva
mer
dpi
mice
bled
dpi
postprim
dpi
postboost
serum
isol
spleen
collect
dpi
splenocyt
harvest
analysi
elispot
intracellular
cytokin
stain
ic
flow
cytometri
previous
describ
use
restimul
merscov
sspecif
peptid
vydtikyysiiphsi
vaccin
cellular
immunogen
g
mva
vectorspecif
peptid
antimva
immun
respons
absenc
peptid
restimul
frequenc
cell
typic
flow
cytometri
less
sfc
elispot
subtract
test
restimul
sampl
captur
antigen
recombin
protein
mybiosourc
ca
usa
use
coat
elisa
plate
standard
endpoint
elisa
protocol
follow
previous
describ
sera
prepar
serial
dilut
pbst
plate
duplic
well
serum
balbc
mous
includ
neg
control
goat
antimous
total
igg
conjug
alkalin
phosphatas
sigma
pnpp
tablet
mg
pnitrophenylphosph
sigma
substrat
use
assay
mer
pseudotyp
viral
particl
merspp
produc
titrat
use
cell
line
describ
previous
merspp
neutralis
assay
serum
sampl
serial
dilut
white
plate
nunc
standard
concentr
merspp
ad
well
plate
incub
h
incub
cell
cell
per
well
ad
plate
duplic
follow
h
incub
cell
lyse
luciferas
activ
measur
neutralis
titr
calcul
mous
serum
sampl
use
graphpad
prism
induct
virusneutralis
antibodi
confirm
accord
previous
publish
protocol
briefli
mous
serum
sampl
test
capac
neutralis
merscov
emc
isol
infect
vitro
tissu
cultur
infect
dose
cell
sera
nonimmunis
mice
serv
neg
control
graphpad
prism
graphpad
softwar
use
statist
analysi
plot
data
anim
procedur
perform
accord
term
uk
anim
scientif
procedur
act
aspa
project
licens
approv
univers
oxford
anim
care
ethic
review
committe
mice
hous
least
day
settlement
prior
procedur
univers
anim
facil
oxford
uk
specif
pathogen
free
spf
condit
spike
gene
camel
isol
merscov
isol
genbank
access
number
clone
four
shuttl
vector
facilit
homolog
recombin
genom
mva
four
recombin
viral
vector
two
two
mva
deriv
describ
materi
method
base
vaccin
candid
gener
without
signal
peptid
human
tissu
plasminogen
activ
gene
tpa
spike
transgen
express
mer
vaccin
candid
control
human
cytomegaloviru
major
immedi
earli
promot
cmv
ie
includ
intron
mva
mer
vaccin
candid
tpa
also
insert
upstream
spike
transgen
control
either
ectop
promot
endogen
promot
fig
merscov
vaccin
candid
contain
codonoptim
spike
transgen
express
newli
synthes
transgen
first
test
transfect
african
green
monkey
kidney
cell
line
vero
cell
adenoviru
shuttl
vector
immunofluoresc
stain
transfect
cell
fig
perform
confirm
express
codon
optim
spike
transgen
mammalian
cell
level
transgen
express
four
vaccin
candid
evalu
vitro
previous
report
differ
mva
promot
activ
detect
vitro
correl
vivo
immunogen
vivo
express
correl
vivo
immunogen
evalu
humor
immun
respons
mer
without
tpa
balbc
mice
vaccin
iu
intramuscularli
serum
sampl
dpi
collect
evalu
elisa
vaccin
candid
induc
high
level
antibodi
mean
endpoint
titr
tpa
without
tpa
unlik
control
vaccin
encod
enhanc
green
fluoresc
protein
mean
endpoint
titr
antibodi
level
similar
two
candid
without
tpa
day
howev
dpi
mer
tpa
induc
significantli
higher
antibodi
mer
without
tpa
mean
endpoint
titr
tpa
without
tpa
fig
serum
sampl
day
select
merspp
neutralis
assay
serum
antibodi
induc
mer
tpa
show
significantli
higher
neutralis
activ
without
tpa
mean
titr
tpa
without
tpa
fig
order
confirm
psuedotyp
viru
neutralis
assay
produc
biolog
relev
result
serum
sampl
mice
immunis
mer
tpa
also
test
neutralis
assay
utilis
wildtyp
mer
viru
assay
confirm
neutralis
activ
mous
antibodi
nab
median
vnt
viru
neutral
test
antibodi
titr
fig
therefor
continu
evalu
mer
tpa
addit
gener
mva
mer
vaccin
candid
tpa
establish
util
tpa
mer
vaccin
refer
mer
rest
report
increas
humor
respons
spleen
collect
dpi
immunis
balbc
mice
splenocyt
process
evalu
cellular
immun
respons
mer
elispot
intracellular
cytokin
stain
ic
peptid
describ
other
use
restimul
cell
assay
elispot
data
show
high
level
secret
splenocyt
median
splenocyt
fig
ic
data
confirm
secret
splenocyt
also
secret
fig
evalu
humor
immun
respons
heterolog
primeboost
vaccin
balbc
mice
immunis
mer
vaccin
boost
one
two
differ
mva
mer
vaccin
candid
four
week
later
mva
base
candid
differ
promot
control
transgen
express
mer
utilis
endogen
strong
earli
promot
mer
utilis
ectop
earlyl
promot
serum
sampl
dpi
postprim
dpi
postboost
collect
evalu
elisa
merspp
neutralis
assay
dpi
mer
induc
similar
level
antibodi
nab
observ
previous
fig
b
dpi
antibodi
boost
higher
level
mean
endpoint
titr
mer
boost
mer
mer
fig
nab
also
enhanc
statist
signific
level
mean
titr
mer
boost
mer
mer
fig
differ
antibodi
level
induc
use
either
promot
mva
dpi
splenocyt
also
process
evalu
cellular
immun
respons
mer
mva
mer
primeboost
vaccin
elispot
ic
shown
fig
cell
respons
mer
boost
mva
vaccin
ic
experi
boost
percentag
splenic
cell
respect
fig
wherea
percentag
mer
prime
fig
percentag
splenic
cell
also
increas
mva
boost
compar
fig
utilis
promot
result
trend
toward
greater
cellmedi
immunogen
fig
splenocyt
also
restimul
mva
backbonespecif
f
g
peptid
evalu
ic
mva
base
vaccin
induc
similar
respons
f
g
peptid
week
mva
vaccin
fig
f
similar
confirm
effici
vaccin
titrat
vaccin
sampl
process
respons
peptid
expect
differ
unless
variat
dose
administ
sampl
prepar
overal
mva
mer
vaccin
abl
boost
humor
cellular
immun
respons
mer
prime
vaccin
differ
promot
result
antibodi
titr
primemva
boost
trend
toward
increas
cellular
immunogen
promot
use
evalu
humor
immun
respons
homolog
mva
mer
primeboost
vaccin
two
group
balbc
mice
immunis
mer
mer
boost
vaccin
three
week
serum
sampl
dpi
postprim
dpi
postboost
collect
evalu
elisa
merspp
neutralis
assay
dpi
mer
induc
similar
level
antibodi
mean
endpoint
titr
respect
fig
dpi
antibodi
level
increas
respect
fig
titr
nab
mer
pp
assay
also
similar
vaccin
mean
titr
mer
respect
fig
utilis
differ
promot
mva
vector
result
differ
induc
antibodi
level
howev
dpi
secret
splenocyt
induc
mer
statist
significantli
higher
mer
median
splenocyt
respect
fig
mva
vaccin
induc
similar
vectorspecif
immun
respons
expect
fig
e
vaccin
merscov
develop
test
number
anim
model
includ
nonhuman
primat
camel
well
human
clinic
trial
vaccin
candid
focus
spike
antigen
contain
receptorbind
domain
use
cell
entri
viru
neutralis
antibodi
may
induc
conserv
therefor
improv
merscov
vaccin
focus
platform
vaccin
regimen
rather
antigen
select
optimis
focus
use
antigen
transgen
develop
vaccin
merscov
assess
differ
vector
differ
version
vector
differ
vaccin
regimen
gener
number
merscov
vaccin
candid
base
codon
optim
spike
transgen
ensur
express
vitro
evalu
humor
cellular
immunogen
preclin
balbc
mous
model
base
vaccin
candid
produc
without
tpa
tpa
signal
peptid
predict
enhanc
humor
immunogen
encod
vaccin
antigen
base
previou
report
data
support
hypothesi
show
signific
increas
antibodi
level
dpi
level
neutralis
antibodi
also
increas
tpa
utilis
howev
mer
without
tpa
still
potent
vaccin
candid
induc
high
level
bind
antibodi
merscov
neutralis
antibodi
neutralis
activ
mous
serum
antibodi
assay
use
merscov
pseudotyp
viral
particl
merspp
approach
use
number
research
human
pathogen
hiv
influenza
hcv
overcom
necess
handl
virus
addit
confirm
abil
serum
sampl
vaccin
mice
neutralis
live
mer
viru
therefor
select
mer
tpa
simpli
refer
mer
evalu
mer
also
induc
cellular
respons
mer
polyfunct
cell
detect
spleen
immunis
mice
support
potenc
viral
vector
induc
cellular
immun
observ
previous
anim
model
well
human
follow
primemva
boost
mva
significantli
boost
neutralis
antibodi
titr
higher
level
differ
humor
immun
found
either
promot
use
regard
promot
effect
mva
cellular
immunogen
previous
report
utilis
promot
enhanc
malaria
influenza
antigen
mva
report
mer
induc
higher
cell
respons
mer
homolog
primeboost
mva
mer
vaccin
vaccin
candid
induc
humor
nab
cellular
immun
polyfunct
cell
respons
merscov
spike
antigen
modest
effect
immunogen
differ
version
vaccin
note
use
tpa
leader
sequenc
use
promot
mva
produc
small
increas
immunogen
compar
leader
sequenc
promot
protect
level
either
antibodi
cellular
immun
requir
counter
merscov
infect
human
anim
model
yet
defin
despit
effort
ideal
vaccin
would
provid
rapid
onset
immun
complet
protect
efficaci
singl
dose
long
durat
immun
complet
protect
efficaci
one
dose
express
extern
glycoprotein
rift
valley
fever
viru
demonstr
multipl
speci
alreadi
known
rvf
highli
immunogen
camel
date
vaccin
mer
test
camel
mva
vector
vaccin
protect
transgen
mice
immunis
homolog
primeboost
regimen
camel
requir
two
dose
given
intranas
intramuscularli
provid
partial
protect
reduct
viru
shed
find
singl
dose
mer
immunogen
two
dose
mva
mer
suggest
regimen
test
protect
efficaci
camel
howev
complet
protect
administr
mva
mer
heterolog
boost
consid
next
hand
one
dose
mva
result
endpoint
titr
log
two
dose
mva
produc
log
one
dose
produc
log
prime
boost
produc
log
singl
dose
mer
protect
two
dose
regimen
requir
would
like
provid
complet
protect
mvamva
mer
evalu
immunogen
efficaci
larger
anim
speci
includ
camel
human
scg
cofound
consult
sharehold
vaccitech
plc
develop
vector
influenza
mer
vaccin
